Search Results

PRECOMBAT

April 4, 2011—Data from the PRECOMBAT study were presented and concurrently published by Seung-Jung Park, MD, et al online ahead of print in The New England Journal of Medicine.

DECISION CTO Compares PCI With Optimal Medical Therapy

March 18, 2017—The American College of Cardiology announced the presentation of data from the DECISION CTO randomized trial by lead investigator Seung-Jung Park, MD, at the ACC 66th annual scientific sessions in Washington, DC.

Cordis Cypher SES Studied in PRECOMBAT to Treat Unprotected Left Main Disease

April 4, 2011—Data from the PRECOMBAT study were presented at the American College of Cardiology's 60th annual scientific session in New Orleans and concurrently published by Seung-Jung Park, MD, et al online ahead of print in The New England Journal of Medicine. The primary objective of the PRECOMBAT trial is to establish the safety and effectiveness of coronary stenting with the sirolimus-eluting balloon-expandable stent (Cypher, Cordis Corporation, Bridgewater, NJ) compared with bypass surgery for the treatment of an unprotected left main coronary artery (LMCA) stenosis.

BEST Trial Finds CABG Outperforms EES for Treating Multivessel CAD

March 16, 2015—The BEST (Bypass Surgery Versus Everolimus-Eluting Stent [EES] Implantation for Multivessel Coronary Artery Disease [CAD]) trial was presented at the 64th annual scientific session of the American College of Cardiology (ACC) in San Diego, California.

PREVENT Investigates Benefits of Preventive PCI for High-Risk Coronary Plaque

April 8, 2024—Two-year data from the PREVENT trial showed that patients who underwent preventive percutaneous coronary intervention (PCI) were 89% less likely to experience the study’s composite primary endpoint of cardiac death, target vessel myocardial infarction (MI), target vessel revascularization, or hospitalization for unstable or progressive chest pain compared with those patients who received medications alone.